Trial Profile

Single-center, Dose-escalation Phase I Tolerability, Safety, Pharmacokinetics and Efficacy of Prilinostat Mesylate (PM) for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant Hematologic Tumors Clinical Trials for Pharmacodynamic Evaluation

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 13 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Purinostat Mesylate Chengdu Zenitar Biomedical Technology (Primary)
Indications Acute biphenotypic leukaemia; B-cell lymphoma; Multiple myeloma; T-cell lymphoma
Focus Pharmacokinetics
Sponsors Chengdu Zenitar Biomedical Technology

01 Oct 2025 Actual primary completion date changed from 7 Jul 2022 to 7 Sep 2022.
16 Jan 2023 Status changed from active, no longer recruiting to completed.
11 Nov 2022 Planned End Date changed from 30 Oct 2022 to 30 Dec 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com